UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in refractory coeliac disease and how to avoid them

Roberto De Giorgio, Giacomo Caio, Umberto Volta

Summary

AI Generated

Refractory coeliac disease is defined by persistent malabsorption and villous atrophy despite strict adherence to a gluten-free diet for over 12 months.

  • RCD diagnosis requires continuation or recurrence of symptoms and signs of malabsorption with villous atrophy in coeliac disease patients who have followed a strict gluten-free diet for more than 12 months
  • Serology in RCD is typically negative, though a small percentage of cases show positive results at low titre
  • Splenic hypofunction is a risk factor for RCD and can be detected by Howell–Jolly bodies and pitted red cells on peripheral blood smear or reduced spleen size on ultrasound
  • This material is relevant for gastroenterologists managing coeliac disease patients with persistent symptoms despite dietary compliance
Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208. [Link]
2.
Al-Toma A, Verbeek WHM and Mulder CJJ. Update on the management of refractory coeliac disease. J Gastrointestin Liver Dis 2007; 16: 57¬–63. [Link]
3.
Rubio-Tapia A and Murray JA. Classification and management of refractory coeliac disease. Gut 2010; 59: 547–557. [Link]
4.
Rubio–Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99–107. [Link]
5.
Di Sabatino A, Brunetti L, Carnevale Maffè G, et al. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 2013; 19: 2313–2318. [Link]
6.
van Wanrooij RLJ, Bouma G, Bontkes HJ, et al. Outcome of referrals for non-responsive celiac disease in a tertiary center: Low incidence of refractory celiac disease in the Netherlands. Clin Transl Gastroenterol 2017; 8: e218. [Link]
7.
van Gils T, Nijeboer P, van Wanrooij RL, et al. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol 2015; 12: 572–579. [Link]
8.
Daum S, Cellier C and Mulder CJJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005; 19: 413–424. [Link]
9.
Malamut G, Meresse B, Cellier C, et al. Refractory celiac disease: From bench to bedside. Semin Immunopathol 2012; 34: 601–613. [Link]
10.
Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30–33. [Link]
11.
Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007; 109: 2243–2249. [Link]
12.
Cellier C, Bouma G, van Gils T et al. [AGA Abstract 616] AMG 714 (ANTI-IL-15 MAB) halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type ii (RCD-II): A phase 2a, randomized, double-blind, placebo-controlled study evaluating AMG 714 in adult patients with RCD-II/PRE-EATL. Gastroenterology 2018; 154 (6) Suppl 1: S-129–S-130. [Link]
13.
Nijeboer P, van Wanrooij R, van Gils T, et al. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor. United Eur Gastroenterol J 2017; 5: 208–217. [Link]
14.
Verbeek WHM, Goerres MS, von Blomberg BME, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol 2008; 126: 48–56. [Link]
15.
Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J 2019; 7: 583–613. [Link]
16.
Roma E, Roubani A, Kolia E, et al. Dietary compliance and life style of children with coeliac disease. J Hum Nutr Diet. 2010; 23: 176–182. [Link]
17.
Aziz I, Peerally MF, Barnes JH, et al. The clinical and phenotypical assessment of seronegative villous atrophy: a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). Gut 2017; 66: 1563–1572. [Link]
18.
Wahab PJ, Meijer JW and Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459–463. [Link]
19.
Volta U and Villanacci V. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol 2011; 8: 96–102. [Link]
20.
Schuppan D, Kelly CP and Krauss N. Monitoring non-responsive patients with celiac disease. Gastrointest Endosc Clin N Am 2006; 16: 593–603. [Link]

Abstract

Refractory coeliac disease (RCD) is characterized by the persistence or recurrence of symptoms and signs of malabsorption associated with villous atrophy in patients with coeliac disease who have adhered to a strict gluten-free diet (GFD) for more than 12 months.1–3 Serology is usually negative or, in a small percentage of cases, positive at a low titre.4 Splenic hypofunction, a risk factor for RCD, can be indicated by Howell–Jolly bodies and pitted red cells in a peripheral blood smear. A reduced spleen size visible on ultrasound examination also provides direct evidence of hyposplenism.5 

Topics

Small Intestine & Nutrition

Citation

Volta U, Caio G and De Giorgio R. Mistakes in refractory coeliac disease and how to avoid them. UEG Education 2019; 19: 15–18.

Published

2025

More Like This:

Mistakes in abdominal distension and how to avoid them

Mistakes in abdominal distension and how to avoid them

Alberto Ezquerra-Durán Alberto Ezquerra-Durán, Elizabeth Barba Orozco

Mistakes in hepatitis C and how to avoid them

Mistakes in hepatitis C and how to avoid them

Gonçalo Alexandrino Gonçalo Alexandrino, Ana Catarina Garcia

Mistakes in chronic diarrhoea and how to avoid them

Mistakes in chronic diarrhoea and how to avoid them

Julian Roger Ford Walters Julian Roger Ford Walters

Mistakes in gastroparesis and how to avoid them

Mistakes in gastroparesis and how to avoid them

Asma Fikree Asma Fikree

Mistakes in acute diverticulitis and how to avoid them

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven Anna A.W. van Geloven, Simone Rottier, Marja A. Boermeester

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Sarah Townsend Sarah Townsend, Philip Newsome

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in abdominal distension and how to avoid them

Elizabeth Barba Orozco, Alberto Ezquerra-Durán

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208. [Link]
2.
Al-Toma A, Verbeek WHM and Mulder CJJ. Update on the management of refractory coeliac disease. J Gastrointestin Liver Dis 2007; 16: 57¬–63. [Link]
3.
Rubio-Tapia A and Murray JA. Classification and management of refractory coeliac disease. Gut 2010; 59: 547–557. [Link]
4.
Rubio–Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99–107. [Link]
5.
Di Sabatino A, Brunetti L, Carnevale Maffè G, et al. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 2013; 19: 2313–2318. [Link]
6.
van Wanrooij RLJ, Bouma G, Bontkes HJ, et al. Outcome of referrals for non-responsive celiac disease in a tertiary center: Low incidence of refractory celiac disease in the Netherlands. Clin Transl Gastroenterol 2017; 8: e218. [Link]
7.
van Gils T, Nijeboer P, van Wanrooij RL, et al. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol 2015; 12: 572–579. [Link]
8.
Daum S, Cellier C and Mulder CJJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005; 19: 413–424. [Link]
9.
Malamut G, Meresse B, Cellier C, et al. Refractory celiac disease: From bench to bedside. Semin Immunopathol 2012; 34: 601–613. [Link]
10.
Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30–33. [Link]
11.
Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007; 109: 2243–2249. [Link]
12.
Cellier C, Bouma G, van Gils T et al. [AGA Abstract 616] AMG 714 (ANTI-IL-15 MAB) halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type ii (RCD-II): A phase 2a, randomized, double-blind, placebo-controlled study evaluating AMG 714 in adult patients with RCD-II/PRE-EATL. Gastroenterology 2018; 154 (6) Suppl 1: S-129–S-130. [Link]
13.
Nijeboer P, van Wanrooij R, van Gils T, et al. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor. United Eur Gastroenterol J 2017; 5: 208–217. [Link]
14.
Verbeek WHM, Goerres MS, von Blomberg BME, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol 2008; 126: 48–56. [Link]
15.
Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J 2019; 7: 583–613. [Link]
16.
Roma E, Roubani A, Kolia E, et al. Dietary compliance and life style of children with coeliac disease. J Hum Nutr Diet. 2010; 23: 176–182. [Link]
17.
Aziz I, Peerally MF, Barnes JH, et al. The clinical and phenotypical assessment of seronegative villous atrophy: a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). Gut 2017; 66: 1563–1572. [Link]
18.
Wahab PJ, Meijer JW and Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459–463. [Link]
19.
Volta U and Villanacci V. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol 2011; 8: 96–102. [Link]
20.
Schuppan D, Kelly CP and Krauss N. Monitoring non-responsive patients with celiac disease. Gastrointest Endosc Clin N Am 2006; 16: 593–603. [Link]

Abstract

Abdominal distension and bloating are among the most frequently misunderstood complaints in gastroenterology. They are often used as interchangeable terms, a conceptual mistake that continues to drive diagnostic errors and ineffective treatment. According to Rome IV, bloating and distension may represent either a primary disorder of gut–brain interaction (DGBI) or occur as symptoms with other DGBIs, such as irritable bowel syndrome (IBS), functional dyspepsia (FD) or functional constipation (FC).

Topics

Neurogastroenterology & Motility

Citation

Barba E and Ezquerra-Durán A. Mistakes in abdominal distension and bloating and how to avoid them. UEG Education 2026; 26: 5-9.

Published

2026

More Like This:

Mistakes in abdominal distension and how to avoid them

Mistakes in abdominal distension and how to avoid them

Alberto Ezquerra-Durán Alberto Ezquerra-Durán, Elizabeth Barba Orozco

Mistakes in hepatitis C and how to avoid them

Mistakes in hepatitis C and how to avoid them

Gonçalo Alexandrino Gonçalo Alexandrino, Ana Catarina Garcia

Mistakes in chronic diarrhoea and how to avoid them

Mistakes in chronic diarrhoea and how to avoid them

Julian Roger Ford Walters Julian Roger Ford Walters

Mistakes in gastroparesis and how to avoid them

Mistakes in gastroparesis and how to avoid them

Asma Fikree Asma Fikree

Mistakes in acute diverticulitis and how to avoid them

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven Anna A.W. van Geloven, Simone Rottier, Marja A. Boermeester

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Sarah Townsend Sarah Townsend, Philip Newsome

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in hepatitis C and how to avoid them

Ana Catarina Garcia, Gonçalo Alexandrino

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208. [Link]
2.
Al-Toma A, Verbeek WHM and Mulder CJJ. Update on the management of refractory coeliac disease. J Gastrointestin Liver Dis 2007; 16: 57¬–63. [Link]
3.
Rubio-Tapia A and Murray JA. Classification and management of refractory coeliac disease. Gut 2010; 59: 547–557. [Link]
4.
Rubio–Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99–107. [Link]
5.
Di Sabatino A, Brunetti L, Carnevale Maffè G, et al. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 2013; 19: 2313–2318. [Link]
6.
van Wanrooij RLJ, Bouma G, Bontkes HJ, et al. Outcome of referrals for non-responsive celiac disease in a tertiary center: Low incidence of refractory celiac disease in the Netherlands. Clin Transl Gastroenterol 2017; 8: e218. [Link]
7.
van Gils T, Nijeboer P, van Wanrooij RL, et al. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol 2015; 12: 572–579. [Link]
8.
Daum S, Cellier C and Mulder CJJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005; 19: 413–424. [Link]
9.
Malamut G, Meresse B, Cellier C, et al. Refractory celiac disease: From bench to bedside. Semin Immunopathol 2012; 34: 601–613. [Link]
10.
Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30–33. [Link]
11.
Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007; 109: 2243–2249. [Link]
12.
Cellier C, Bouma G, van Gils T et al. [AGA Abstract 616] AMG 714 (ANTI-IL-15 MAB) halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type ii (RCD-II): A phase 2a, randomized, double-blind, placebo-controlled study evaluating AMG 714 in adult patients with RCD-II/PRE-EATL. Gastroenterology 2018; 154 (6) Suppl 1: S-129–S-130. [Link]
13.
Nijeboer P, van Wanrooij R, van Gils T, et al. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor. United Eur Gastroenterol J 2017; 5: 208–217. [Link]
14.
Verbeek WHM, Goerres MS, von Blomberg BME, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol 2008; 126: 48–56. [Link]
15.
Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J 2019; 7: 583–613. [Link]
16.
Roma E, Roubani A, Kolia E, et al. Dietary compliance and life style of children with coeliac disease. J Hum Nutr Diet. 2010; 23: 176–182. [Link]
17.
Aziz I, Peerally MF, Barnes JH, et al. The clinical and phenotypical assessment of seronegative villous atrophy: a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). Gut 2017; 66: 1563–1572. [Link]
18.
Wahab PJ, Meijer JW and Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459–463. [Link]
19.
Volta U and Villanacci V. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol 2011; 8: 96–102. [Link]
20.
Schuppan D, Kelly CP and Krauss N. Monitoring non-responsive patients with celiac disease. Gastrointest Endosc Clin N Am 2006; 16: 593–603. [Link]

Abstract

Hepatitis C virus (HCV) infection remains an important global health concern. It is estimated that there are approximately 50 million people infected with HCV globally, with around 1 million new infections each year and about 242,000 deaths annually attributed to HCV-related complications. Most acute HCV infections (55–85%) become chronic due to the virus’s effective evasion strategies, with spontaneous clearance being rare once chronicity is established. This condition often progresses silently, with many individuals unaware of their infection until advanced liver damage has occurred. If left untreated, HCV can lead to severe complications, including liver cirrhosis and hepatocellular carcinoma (HCC). HCV transmission occurs mainly through percutaneous exposure to infected blood. HCV can also spread from mother to infant (vertical transmission) and, less frequently, via sexual contact.1,2 In recent years, the introduction of oral direct-acting antivirals (DAAs), with remarkable safety and effectiveness profiles, has led to a sustained virological response (SVR) in virtually all (>97%) HCV-infected patients, regardless of HCV genotype or disease stage. However, significant barriers remain, such as issues with diagnosis, access to treatment and awareness of the disease.

Here, we discuss some of the misconceptions in HCV management and provide a practical management approach grounded in evidence and clinical experience.

Topics

Hepatobiliary

Citation

Garcia A.C and Alexandrino G. Mistakes in hepatits C and how to avoid them. UEG Education 2025; 25: 14-17.

Published

2025

More Like This:

Mistakes in abdominal distension and how to avoid them

Mistakes in abdominal distension and how to avoid them

Alberto Ezquerra-Durán Alberto Ezquerra-Durán, Elizabeth Barba Orozco

Mistakes in hepatitis C and how to avoid them

Mistakes in hepatitis C and how to avoid them

Gonçalo Alexandrino Gonçalo Alexandrino, Ana Catarina Garcia

Mistakes in chronic diarrhoea and how to avoid them

Mistakes in chronic diarrhoea and how to avoid them

Julian Roger Ford Walters Julian Roger Ford Walters

Mistakes in gastroparesis and how to avoid them

Mistakes in gastroparesis and how to avoid them

Asma Fikree Asma Fikree

Mistakes in acute diverticulitis and how to avoid them

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven Anna A.W. van Geloven, Simone Rottier, Marja A. Boermeester

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Sarah Townsend Sarah Townsend, Philip Newsome

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in chronic diarrhoea and how to avoid them

Julian Roger Ford Walters

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208. [Link]
2.
Al-Toma A, Verbeek WHM and Mulder CJJ. Update on the management of refractory coeliac disease. J Gastrointestin Liver Dis 2007; 16: 57¬–63. [Link]
3.
Rubio-Tapia A and Murray JA. Classification and management of refractory coeliac disease. Gut 2010; 59: 547–557. [Link]
4.
Rubio–Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99–107. [Link]
5.
Di Sabatino A, Brunetti L, Carnevale Maffè G, et al. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 2013; 19: 2313–2318. [Link]
6.
van Wanrooij RLJ, Bouma G, Bontkes HJ, et al. Outcome of referrals for non-responsive celiac disease in a tertiary center: Low incidence of refractory celiac disease in the Netherlands. Clin Transl Gastroenterol 2017; 8: e218. [Link]
7.
van Gils T, Nijeboer P, van Wanrooij RL, et al. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol 2015; 12: 572–579. [Link]
8.
Daum S, Cellier C and Mulder CJJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005; 19: 413–424. [Link]
9.
Malamut G, Meresse B, Cellier C, et al. Refractory celiac disease: From bench to bedside. Semin Immunopathol 2012; 34: 601–613. [Link]
10.
Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30–33. [Link]
11.
Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007; 109: 2243–2249. [Link]
12.
Cellier C, Bouma G, van Gils T et al. [AGA Abstract 616] AMG 714 (ANTI-IL-15 MAB) halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type ii (RCD-II): A phase 2a, randomized, double-blind, placebo-controlled study evaluating AMG 714 in adult patients with RCD-II/PRE-EATL. Gastroenterology 2018; 154 (6) Suppl 1: S-129–S-130. [Link]
13.
Nijeboer P, van Wanrooij R, van Gils T, et al. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor. United Eur Gastroenterol J 2017; 5: 208–217. [Link]
14.
Verbeek WHM, Goerres MS, von Blomberg BME, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol 2008; 126: 48–56. [Link]
15.
Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J 2019; 7: 583–613. [Link]
16.
Roma E, Roubani A, Kolia E, et al. Dietary compliance and life style of children with coeliac disease. J Hum Nutr Diet. 2010; 23: 176–182. [Link]
17.
Aziz I, Peerally MF, Barnes JH, et al. The clinical and phenotypical assessment of seronegative villous atrophy: a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). Gut 2017; 66: 1563–1572. [Link]
18.
Wahab PJ, Meijer JW and Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459–463. [Link]
19.
Volta U and Villanacci V. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol 2011; 8: 96–102. [Link]
20.
Schuppan D, Kelly CP and Krauss N. Monitoring non-responsive patients with celiac disease. Gastrointest Endosc Clin N Am 2006; 16: 593–603. [Link]

Abstract

Chronic diarrhoea, lasting more than 3 or 4 weeks, is a common condition with a wide variety of different possible causes. Estimates suggest 5% of the population have experienced chronic diarrhoea and sought medical advice about it. All gastroenterologists see many patients whose principal complaint is frequent, loose stools, and will be aware of investigations that are needed to diagnose serious conditions such as inflammatory bowel disease (IBD) or colorectal cancer (CRC). Most people who present with chronic diarrhoea will not have these conditions and, if less common disorders are not considered, may be given a diagnosis of diarrhoea-predominant irritable bowel syndrome (IBS-D) or perhaps functional diarrhoea. Many different treatments are used for IBS-D and often benefit only a small proportion of patients, leaving many with unmet needs, seeking further investigation, advice and treatment.

Topics

Neurogastroenterology & Motility

Citation

Walters JRF. Mistakes in chronic diarrhoea and how to avoid them. UEG Education 2019; 19: 1–4.

Published

2019

More Like This:

Mistakes in abdominal distension and how to avoid them

Mistakes in abdominal distension and how to avoid them

Alberto Ezquerra-Durán Alberto Ezquerra-Durán, Elizabeth Barba Orozco

Mistakes in hepatitis C and how to avoid them

Mistakes in hepatitis C and how to avoid them

Gonçalo Alexandrino Gonçalo Alexandrino, Ana Catarina Garcia

Mistakes in chronic diarrhoea and how to avoid them

Mistakes in chronic diarrhoea and how to avoid them

Julian Roger Ford Walters Julian Roger Ford Walters

Mistakes in gastroparesis and how to avoid them

Mistakes in gastroparesis and how to avoid them

Asma Fikree Asma Fikree

Mistakes in acute diverticulitis and how to avoid them

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven Anna A.W. van Geloven, Simone Rottier, Marja A. Boermeester

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Sarah Townsend Sarah Townsend, Philip Newsome

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in gastroparesis and how to avoid them

Asma Fikree

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208. [Link]
2.
Al-Toma A, Verbeek WHM and Mulder CJJ. Update on the management of refractory coeliac disease. J Gastrointestin Liver Dis 2007; 16: 57¬–63. [Link]
3.
Rubio-Tapia A and Murray JA. Classification and management of refractory coeliac disease. Gut 2010; 59: 547–557. [Link]
4.
Rubio–Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99–107. [Link]
5.
Di Sabatino A, Brunetti L, Carnevale Maffè G, et al. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 2013; 19: 2313–2318. [Link]
6.
van Wanrooij RLJ, Bouma G, Bontkes HJ, et al. Outcome of referrals for non-responsive celiac disease in a tertiary center: Low incidence of refractory celiac disease in the Netherlands. Clin Transl Gastroenterol 2017; 8: e218. [Link]
7.
van Gils T, Nijeboer P, van Wanrooij RL, et al. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol 2015; 12: 572–579. [Link]
8.
Daum S, Cellier C and Mulder CJJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005; 19: 413–424. [Link]
9.
Malamut G, Meresse B, Cellier C, et al. Refractory celiac disease: From bench to bedside. Semin Immunopathol 2012; 34: 601–613. [Link]
10.
Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30–33. [Link]
11.
Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007; 109: 2243–2249. [Link]
12.
Cellier C, Bouma G, van Gils T et al. [AGA Abstract 616] AMG 714 (ANTI-IL-15 MAB) halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type ii (RCD-II): A phase 2a, randomized, double-blind, placebo-controlled study evaluating AMG 714 in adult patients with RCD-II/PRE-EATL. Gastroenterology 2018; 154 (6) Suppl 1: S-129–S-130. [Link]
13.
Nijeboer P, van Wanrooij R, van Gils T, et al. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor. United Eur Gastroenterol J 2017; 5: 208–217. [Link]
14.
Verbeek WHM, Goerres MS, von Blomberg BME, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol 2008; 126: 48–56. [Link]
15.
Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J 2019; 7: 583–613. [Link]
16.
Roma E, Roubani A, Kolia E, et al. Dietary compliance and life style of children with coeliac disease. J Hum Nutr Diet. 2010; 23: 176–182. [Link]
17.
Aziz I, Peerally MF, Barnes JH, et al. The clinical and phenotypical assessment of seronegative villous atrophy: a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). Gut 2017; 66: 1563–1572. [Link]
18.
Wahab PJ, Meijer JW and Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459–463. [Link]
19.
Volta U and Villanacci V. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol 2011; 8: 96–102. [Link]
20.
Schuppan D, Kelly CP and Krauss N. Monitoring non-responsive patients with celiac disease. Gastrointest Endosc Clin N Am 2006; 16: 593–603. [Link]

Abstract

The term ‘gastroparesis’ was first coined by Kassander in 1958 to describe the fact that barium did not leave the stomach of patients with diabetes for over 24 hours — so-called ‘gastroparesis diabeticorum’. Nowadays it refers to a delay in gastric emptying that is associated with symptoms primarily of nausea and vomiting as well as the absence of mechanical obstruction. In 1958, 21 cases were described, but in 2019, 5 million US individuals were diagnosed as having gastroparesis. This rapid increase in prevalence is likely to have occurred because it has become much easier to measure gastric emptying and to attribute symptoms to this without necessarily thinking through differentials. The incidence of hospital admissions for patients labelled as having gastroparesis is rapidly rising, increasing at a much faster rate than admissions for patients with nausea and vomiting, gastro-oesophageal reflux disease, gastritis or gastric ulcers, which are all remaining relatively static. Gastroparesis therefore represents a major healthcare burden. Gastroparesis can be idiopathic or is most frequently caused by diabetes (type 1 more than type 2) or surgical procedures that can disrupt the vagus nerve (e.g. Billroth gastrectomy, oesophagectomy, gastric bypass surgery and fundoplication). In this article, I describe the mistakes most frequently made in patients who have a suspected diagnosis of gastroparesis. I base my discussion on the available evidence as well as clinical experience in the field. 


Topics

Neurogastroenterology & Motility Stomach & H. Pylori

Citation

Fikree A. Mistakes in gastroparesis and how to avoid them. UEG Education 2021; 21: 18–22.

Published

2021

More Like This:

Mistakes in abdominal distension and how to avoid them

Mistakes in abdominal distension and how to avoid them

Alberto Ezquerra-Durán Alberto Ezquerra-Durán, Elizabeth Barba Orozco

Mistakes in hepatitis C and how to avoid them

Mistakes in hepatitis C and how to avoid them

Gonçalo Alexandrino Gonçalo Alexandrino, Ana Catarina Garcia

Mistakes in chronic diarrhoea and how to avoid them

Mistakes in chronic diarrhoea and how to avoid them

Julian Roger Ford Walters Julian Roger Ford Walters

Mistakes in gastroparesis and how to avoid them

Mistakes in gastroparesis and how to avoid them

Asma Fikree Asma Fikree

Mistakes in acute diverticulitis and how to avoid them

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven Anna A.W. van Geloven, Simone Rottier, Marja A. Boermeester

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Sarah Townsend Sarah Townsend, Philip Newsome

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven, Simone Rottier, Marja A. Boermeester

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208. [Link]
2.
Al-Toma A, Verbeek WHM and Mulder CJJ. Update on the management of refractory coeliac disease. J Gastrointestin Liver Dis 2007; 16: 57¬–63. [Link]
3.
Rubio-Tapia A and Murray JA. Classification and management of refractory coeliac disease. Gut 2010; 59: 547–557. [Link]
4.
Rubio–Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99–107. [Link]
5.
Di Sabatino A, Brunetti L, Carnevale Maffè G, et al. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 2013; 19: 2313–2318. [Link]
6.
van Wanrooij RLJ, Bouma G, Bontkes HJ, et al. Outcome of referrals for non-responsive celiac disease in a tertiary center: Low incidence of refractory celiac disease in the Netherlands. Clin Transl Gastroenterol 2017; 8: e218. [Link]
7.
van Gils T, Nijeboer P, van Wanrooij RL, et al. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol 2015; 12: 572–579. [Link]
8.
Daum S, Cellier C and Mulder CJJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005; 19: 413–424. [Link]
9.
Malamut G, Meresse B, Cellier C, et al. Refractory celiac disease: From bench to bedside. Semin Immunopathol 2012; 34: 601–613. [Link]
10.
Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30–33. [Link]
11.
Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007; 109: 2243–2249. [Link]
12.
Cellier C, Bouma G, van Gils T et al. [AGA Abstract 616] AMG 714 (ANTI-IL-15 MAB) halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type ii (RCD-II): A phase 2a, randomized, double-blind, placebo-controlled study evaluating AMG 714 in adult patients with RCD-II/PRE-EATL. Gastroenterology 2018; 154 (6) Suppl 1: S-129–S-130. [Link]
13.
Nijeboer P, van Wanrooij R, van Gils T, et al. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor. United Eur Gastroenterol J 2017; 5: 208–217. [Link]
14.
Verbeek WHM, Goerres MS, von Blomberg BME, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol 2008; 126: 48–56. [Link]
15.
Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J 2019; 7: 583–613. [Link]
16.
Roma E, Roubani A, Kolia E, et al. Dietary compliance and life style of children with coeliac disease. J Hum Nutr Diet. 2010; 23: 176–182. [Link]
17.
Aziz I, Peerally MF, Barnes JH, et al. The clinical and phenotypical assessment of seronegative villous atrophy: a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). Gut 2017; 66: 1563–1572. [Link]
18.
Wahab PJ, Meijer JW and Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459–463. [Link]
19.
Volta U and Villanacci V. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol 2011; 8: 96–102. [Link]
20.
Schuppan D, Kelly CP and Krauss N. Monitoring non-responsive patients with celiac disease. Gastrointest Endosc Clin N Am 2006; 16: 593–603. [Link]

Abstract

Acute diverticulitis is an inflammatory complication of diverticulosis and can either be uncomplicated or complicated. Making the distinction between uncomplicated and complicated acute diverticulitis is essential because treatment strategies differ between the two. Here, we discuss 10 mistakes frequently made when managing patients with acute diverticulitis. We focus on using the correct terminology, diagnostic preference and several treatment options, such as omitting or administering antibiotics, radiological interventions and various aspects of surgery. Acute diverticulitis is an important topic because its incidence is rising worldwide and it is becoming a considerable burden on healthcare systems. Most of the discussion included here is evidence-based, supplemented with many years’ combined clinical experience where evidence is lacking.

Topics

Endoscopy Radiology & Imaging Surgery

Citation

Cite this article as: Rottier SJ, et al. Mistakes in acute diverticulitis and how to avoid them. UEG Education 2019; 19: 31–35.

Published

2019

More Like This:

Mistakes in abdominal distension and how to avoid them

Mistakes in abdominal distension and how to avoid them

Alberto Ezquerra-Durán Alberto Ezquerra-Durán, Elizabeth Barba Orozco

Mistakes in hepatitis C and how to avoid them

Mistakes in hepatitis C and how to avoid them

Gonçalo Alexandrino Gonçalo Alexandrino, Ana Catarina Garcia

Mistakes in chronic diarrhoea and how to avoid them

Mistakes in chronic diarrhoea and how to avoid them

Julian Roger Ford Walters Julian Roger Ford Walters

Mistakes in gastroparesis and how to avoid them

Mistakes in gastroparesis and how to avoid them

Asma Fikree Asma Fikree

Mistakes in acute diverticulitis and how to avoid them

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven Anna A.W. van Geloven, Simone Rottier, Marja A. Boermeester

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Sarah Townsend Sarah Townsend, Philip Newsome

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Sarah Townsend, Philip Newsome

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208. [Link]
2.
Al-Toma A, Verbeek WHM and Mulder CJJ. Update on the management of refractory coeliac disease. J Gastrointestin Liver Dis 2007; 16: 57¬–63. [Link]
3.
Rubio-Tapia A and Murray JA. Classification and management of refractory coeliac disease. Gut 2010; 59: 547–557. [Link]
4.
Rubio–Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99–107. [Link]
5.
Di Sabatino A, Brunetti L, Carnevale Maffè G, et al. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 2013; 19: 2313–2318. [Link]
6.
van Wanrooij RLJ, Bouma G, Bontkes HJ, et al. Outcome of referrals for non-responsive celiac disease in a tertiary center: Low incidence of refractory celiac disease in the Netherlands. Clin Transl Gastroenterol 2017; 8: e218. [Link]
7.
van Gils T, Nijeboer P, van Wanrooij RL, et al. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol 2015; 12: 572–579. [Link]
8.
Daum S, Cellier C and Mulder CJJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005; 19: 413–424. [Link]
9.
Malamut G, Meresse B, Cellier C, et al. Refractory celiac disease: From bench to bedside. Semin Immunopathol 2012; 34: 601–613. [Link]
10.
Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30–33. [Link]
11.
Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007; 109: 2243–2249. [Link]
12.
Cellier C, Bouma G, van Gils T et al. [AGA Abstract 616] AMG 714 (ANTI-IL-15 MAB) halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type ii (RCD-II): A phase 2a, randomized, double-blind, placebo-controlled study evaluating AMG 714 in adult patients with RCD-II/PRE-EATL. Gastroenterology 2018; 154 (6) Suppl 1: S-129–S-130. [Link]
13.
Nijeboer P, van Wanrooij R, van Gils T, et al. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor. United Eur Gastroenterol J 2017; 5: 208–217. [Link]
14.
Verbeek WHM, Goerres MS, von Blomberg BME, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol 2008; 126: 48–56. [Link]
15.
Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J 2019; 7: 583–613. [Link]
16.
Roma E, Roubani A, Kolia E, et al. Dietary compliance and life style of children with coeliac disease. J Hum Nutr Diet. 2010; 23: 176–182. [Link]
17.
Aziz I, Peerally MF, Barnes JH, et al. The clinical and phenotypical assessment of seronegative villous atrophy: a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). Gut 2017; 66: 1563–1572. [Link]
18.
Wahab PJ, Meijer JW and Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459–463. [Link]
19.
Volta U and Villanacci V. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol 2011; 8: 96–102. [Link]
20.
Schuppan D, Kelly CP and Krauss N. Monitoring non-responsive patients with celiac disease. Gastrointest Endosc Clin N Am 2006; 16: 593–603. [Link]

Abstract

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a subclassification of steatotic liver disease (SLD), defined as the presence of excess triglyceride storage in the liver in conjunction with at least one cardiometabolic risk factor and no other discernible cause.1 Cirrhosis secondary to MASH is the most common cause of liver disease in the world and is the fastest-growing indication for liver transplantation, but it also has a >50% recurrence rate post-transplantation.

Topics

Hepatobiliary

Citation

Townsend SA and Newsome PN. Mistakes in nonalcoholic fatty liver disease and how to avoid them. UEG Education 2017; 17: 39–41.

Published

2024

More Like This:

Mistakes in abdominal distension and how to avoid them

Mistakes in abdominal distension and how to avoid them

Alberto Ezquerra-Durán Alberto Ezquerra-Durán, Elizabeth Barba Orozco

Mistakes in hepatitis C and how to avoid them

Mistakes in hepatitis C and how to avoid them

Gonçalo Alexandrino Gonçalo Alexandrino, Ana Catarina Garcia

Mistakes in chronic diarrhoea and how to avoid them

Mistakes in chronic diarrhoea and how to avoid them

Julian Roger Ford Walters Julian Roger Ford Walters

Mistakes in gastroparesis and how to avoid them

Mistakes in gastroparesis and how to avoid them

Asma Fikree Asma Fikree

Mistakes in acute diverticulitis and how to avoid them

Mistakes in acute diverticulitis and how to avoid them

Anna A.W. van Geloven Anna A.W. van Geloven, Simone Rottier, Marja A. Boermeester

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Mistakes in metabolic dysfunction associated steatotic liver disease and how to avoid them

Sarah Townsend Sarah Townsend, Philip Newsome

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.